SODIUM FLUORIDE F 18 injection

Sodium Fluoride by

Drug Labeling and Warnings

Sodium Fluoride by is a Prescription medication manufactured, distributed, or labeled by Shertech Laboratories, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Sodium Fluoride F18 Injection, USP is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Radiation Safety - Drug Handling

    • Wear waterproof gloves and effective shielding when handling Sodium Fluoride F18 Injection. Use appropriate safety measures, including shielding, consistent with proper patient management to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel, and other persons.
    • Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
    • Use aseptic technique to maintain sterility during all operations involved in the manipulation and administration of Sodium Fluoride F18 Injection.
    • The dose of Sodium Fluoride F18 Injection should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed.
    • The final dose for the patient should be calculated using proper decay factors from the time of End of Synthesis (EOS), and measured by a suitable radioactivity calibration system before administration {see Description (11.2)] .

    2.2 Radiation Safety - Patient Preparation

    • To minimize the radiation-absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to ingest at least 500 mL of fluid immediately prior and subsequent to the administration of Sodium Fluoride F18 Injection.
    • Encourage the patient to void one-half hour after administration of Sodium Fluoride F18 Injection and as frequently thereafter as possible for the next 12 hours.

    2.3 Drug Preparation and Administration

    • Calculate the necessary volume to administer based on calibration time and dose.
    • Inspect Sodium Fluoride F18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit.
    • Do not administer Sodium Fluoride F18 Injection containing particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations.
    • Aseptically withdraw Sodium Fluoride F18 Injection from its container.

    2.4 Recommended Dose for Adults

    Administer 300–450 MBq (8–12 mCi) as an intravenous injection.

    2.5 Recommended Dose for Pediatric Patients

    In reported clinical experience in approximately 100 children, weight based doses (2.1 MBq/kg) ranging from 19 MBq–148 MBq (0.5 mCi–4 mCi) were used.

    2.6 Radiation Dosimetry

    The age/weight- based estimated absorbed radiation doses (mGy/MBq) from intravenous injection of Sodium Fluoride F18 Injection are shown in Table 1. These estimates were calculated based on human data and using the data published by the Nuclear Regulatory Commission [1] and the International Commission on Radiological Protection for Sodium Fluoride Injection [2]. The bone, bone marrow and urinary bladder are considered target and critical organs.

    Table 1. Estimated Absorbed Radiation Doses after Intravenous Administration of Sodium Fluoride F18 Injection
    Organ Estimated Radiation Dose mGy/MBq
    Adult
    70 kg [1]     		15 year
    56.8 kg [2]     		10 year
    33.2 kg [2]     		5 year
    19.8 kg [2]     		1 year
    9.7 kg [2]
    Adrenals 0.0062 0.012 0.018 0.028 0.052
    Brain 0.0056 N/A N/A N/A N/A
    Bone surfaces 0.060 0.050 0.079 0.13 0.30
    Breasts 0.0028 0.0061 0.0097 0.015 0.030
    GI Gallbladder wall 0.0044 N/A N/A N/A N/A
    Stomach wall 0.0038 0.008 0.013 0.019 0.036
    Small intestine 0.0066 0.012 0.018 0.028 0.052
    Upper large intestine wall 0.0058 0.010 0.016 0.026 0.046
    Lower large intestine wall 0.012 0.016 0.025 0.037 0.063
    Heart wall 0.0039 N/A N/A N/A N/A
    Kidneys 0.019 0.025 0.036 0.053 0.097
    Liver 0.0040 0.0084 0.013 0.021 0.039
    Lungs 0.0041 0.0084 0.013 0.020 0.039
    Muscle 0.0060 N/A N/A N/A N/A
    Ovaries 0.011 0.016 0.023 0.036 0.063
    Pancreas 0.0048 0.0096 0.015 0.023 0.044
    Red marrow 0.028 0.053 0.088 0.18 0.38
    Skin 0.0040 N/A N/A N/A N/A
    Spleen 0.0042 0.0088 0.014 0.021 0.041
    Testes 0.0078 0.013 0.021 0.033 0.062
    Thymus 0.0035 N/A N/A N/A N/A
    Thyroid 0.0044 0.0084 0.013 0.020 0.036
    Urinary bladder wall 0.25 0.27 0.4 0.61 1.1
    Uterus 0.019 0.023 0.037 0.057 0.099
    Other tissue N/A 0.010 0.015 0.024 0.044
    Effective Dose
    Equivalent mSv/MBq     		0.027 0.034 0.052 0.086 0.17

    [1] Data from Nuclear Regulatory Commission Report, Radiation Dose Estimates for Radiopharmaceuticals, NUREG/CR-6345, page 10, 1996.

    [2] Data from ICRP publication 53, Radiation Dose to Patients from Radiopharmaceuticals, Ann ICRP, Volume 18, pages 15 and 74, 1987

    2.7 Imaging Guidelines

    • Imaging of Sodium Fluoride F18 Injection can begin 1 hour – 2 hours after administration; optimally at 1 hour post administration.
    • Encourage the patient to void immediately prior to imaging the fluoride F18 radioactivity in the lumbar spine or bony pelvis.
  • 3 DOSAGE FORMS AND STRENGTHS

    Multiple-dose vial containing 374 MBq/mL – 7,400 MBq/mL (10 mCi/mL – 200 mCi/mL) at EOS reference time of no-carrier-added sodium fluoride F18 in aqueous 0.9% sodium chloride solution. Sodium Fluoride F18 Injection is a clear, colorless, sterile, pyrogen-free and preservative-free solution for intravenous administration.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Allergic Reactions

    As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available.

    5.2 Radiation Risks

    Sodium Fluoride F18 Injection may increase the risk of cancer. Carcinogenic and mutagenic studies with Sodium Fluoride F18 injection have not been performed. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [see Dosage and Administration (2.1)] .

  • 6 ADVERSE REACTIONS

    No adverse reactions have been reported for Sodium Fluoride F18 Injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems. However, the completeness of these sources is not known.

  • 7 DRUG INTERACTIONS

    The possibility of interactions of Sodium Fluoride F18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category C

    Any radiopharmaceutical including Sodium Fluoride F18 Injection has a potential to cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. Animal reproduction and developmental toxicity studies have not been conducted with Sodium Fluoride F18 Injection. Prior to the administration of Sodium Fluoride F18 Injection to women of childbearing potential, assess for presence of pregnancy. Sodium Fluoride F18 Injection should be given to a pregnant woman only if clearly needed.

    8.3 Nursing Mothers

    It is not known whether Sodium Fluoride F18 Injection is excreted into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of Sodium Fluoride F18 Injection or not to administer Sodium Fluoride F18 Injection, taking into account the importance of the drug to the mother. The body of scientific information related to radioactivity decay, drug tissue distribution and drug elimination shows that less than 0.01% of the radioactivity administered remains in the body after 24 hours (10 half-lives). To minimize the risks to a nursing infant, interrupt nursing for at least 24 hours.

    8.4 Pediatric Use

    In reported clinical experience in approximately 100 children, weight based doses (2.1 MBq/kg) ranging from 19 MBq–148 MBq (0.5 mCi - 4 mCi) were used. Sodium Fluoride F18 was shown to localize to areas of bone turnover including rapidly growing epiphyses in developing long bones. Children are more sensitive to radiation and may be at higher risk of cancer from Sodium Fluoride F18 injection.

  • 11 DESCRIPTION

    11.1 Chemical Characteristics

    Sodium Fluoride F18 Injection, USP is a positron emitting radiopharmaceutical, containing no-carrier-added, radioactive fluoride F18 that is used for diagnostic purposes in conjunction with PET imaging. It is administered by intravenous injection. The active ingredient, sodium fluoride F18, has the molecular formula Na[ 18F] with a molecular weight of 40.99, and has the following chemical structure:

    Na+ 18F-

    Sodium Fluoride F18 Injection, USP is provided as a ready-to-use, isotonic, sterile, pyrogen-free, preservative-free, clear and colorless solution. Each mL of the solution contains between 374 MBq to 7,400 MBq (10 mCi to 200 mCi) sodium fluoride F18, at the EOS reference time, in 0.9% aqueous sodium chloride. The pH of the solution is between 4.5 and 8. The solution is presented in 10 mL and 30 mL multiple- dose glass vials with variable total volume and total radioactivity in each vial.

    11.2 Physical Characteristics

    Fluoride F18 decays by positron (β+) emission and has a half-life of 109.7 minutes. Ninety-seven percent of the decay results in emission of a positron with a maximum energy of 633 keV and 3% of the decay results in electron capture with subsequent emission of characteristic X-rays of oxygen. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 2). Fluorine F18 atom decays to stable 18O-oxygen.

    Table 2: Principal Emission Data for Fluoride F18
    Radiation/Emission% per DisintegrationMean Energy
  • * Produced by positron annihilation [3] Kocher, D.C. Radioactive Decay Data Tables DOE/TIC-11026, 69, 1981.
    • Positron (β+)96.73249.8 keV
    Gamma (±) *193.46511.0 keV

    The specific gamma ray constant (point source air kerma coefficient) for fluoride F18 is 5.7 R/hr/mCi (1.35 x 10 -6 Gy/hr/kBq) at 1 cm. The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb). A range of values for the attenuation of radiation results from the interposition of various thickness of Pb. The range of attenuation coefficients for this radionuclide is shown in Table 3. For example, the interposition of an 8 mm thickness of Pb with a coefficient of attenuation of 0.25 will decrease the external radiation by 75%.

    Table 3:Radiation Attenuation of 511 keV Photons by Lead (Pb) Shielding
    Shield Thickness (Pb) mmCoefficient of Attenuation
    00.00
    40.50
    80.25
    130.10
    260.01
    390.001
    520.0001

    Table 4 lists the fraction of radioactivity remaining at selected time intervals from the calibration time. This information may be used to correct for physical decay of the radionuclide.

    Table 4: Physical Decay Chart for Fluoride F18
    Time Since CalibrationFraction Remaining
  • * Calibration time
    		•
    0 *1.00
    15 minutes0.909
    30 minutes0.826
    60 minutes0.683
    110 minutes0.500
    220 minutes0.250
    440 minutes0.060
    12 hours0.011
    24 hours0.0001
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Fluoride F18 ion normally accumulates in the skeleton in an even fashion, with greater deposition in the axial skeleton (e.g. vertebrae and pelvis) than in the appendicular skeleton and greater deposition in the bones around joints than in the shafts of long bones.

    12.2 Pharmacodynamics

    Increased fluoride F18 ion deposition in bone can occur in areas of increased osteogenic activity during growth, infection, malignancy (primary or metastatic) following trauma, or inflammation of bone.

    12.3 Pharmacokinetics

    After intravenous administration, fluoride F18 ion is rapidly cleared from the plasma in a biexponential manner. The first phase has a half-life of 0.4 h, and the second phase has a half-life of 2.6 h. Essentially all the fluoride F18 that is delivered to bone by the blood is retained in the bone. One hour after administration of fluoride F18 only about 10% of the injected dose remains in the blood. Fluoride F18 diffuses through capillaries into bone extracellular fluid space, where it becomes bound by chemisorption at the surface of bone crystals, preferentially at sites of newly mineralizing bone.

    Deposition of fluoride F18 in bone appears to be primarily a function of blood flow to the bone and the efficiency of the bone in extracting the fluoride F18. Fluoride F18 does not appear to be bound to serum proteins.

    In patients with normal renal function, 20% or more of the fluorine ion is cleared from the body in the urine within the first 2 hours after intravenous administration.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies to assess reproductive toxicity, mutagenesis and carcinogenesis potential of Sodium Fluoride F18 Injection have not been performed.

  • 14 CLINICAL STUDIES

    14.1 Metastatic Bone Desease

    The doses used in reported studies ranged from 2.7 mCi to 20 mCi (100 MBq to 740 MBq), with an average median dose of 10 mCi (370 MBq) and an average mean dose of 9.2 mCi (340 MBq). In PET imaging of bone metastases with Sodium Fluoride F18 Injection, focally increased tracer uptake is seen in both osteolytic and osteoblastic bone lesions. Negative PET imaging results with Sodium Fluoride F18 Injection do not preclude the diagnosis of bone metastases. Also, as benign bone lesions are also detected by Sodium Fluoride F18 Injection, positive PET imaging results cannot replace biopsy to confirm a diagnosis of cancer.

    14.2 Other Bone Disorders

    The doses used in reported studies ranged from 2.43 mCi to 15 mCi (90 MBq to 555 MBq), with an average median dose of 8.0 mCi (300 MBq) and an average mean dose of 7.6 mCi (280 MBq).

  • 15 REFERENCES

    1. Stablin, M.G., Stubbs, J.B. and Toohey R.E., Radiation Dose Estimates for Radiopharmaceuticals, U.S. Nuclear Regulatory Commission report NUREG/CR-6345, page 10, 1996.
    2. Radiation Dose to Patients from Radiopharmaceuticals, ICRP publication 53, Ann ICRP, 18 pages 15 and 74, 1987.
    3. Kocher, D.C., "Radioactive Decay Data Tables: A Handbook of decay data for application to radiation dosimetry and radiological assessments" DOE/TIC-11026, page 69, 1981.
  • 16 HOW SUPPLIED

    Sodium Fluoride F18 Injection, USP is supplied in a multiple-dose Type I glass vial with (elastomeric) stopper and aluminum crimp seal containing between 374 MBq/mL - 7,400 MBq/mL (10 mCi/mL - 200 mCi/mL) of no-carrier-added sodium fluoride F18, at the EOS reference time, in aqueous 0.9% sodium chloride solution. The total volume and total radioactivity per vial are variable. Each vial is enclosed in a shielding container of appropriate thickness.

    The product is available in a 30 mL vial configuration with a variable fill volume. The NDC number is:

    16129-002-30 (30 mL)

    The product is available in a 10 mL vial configuration with a variable fill volume. The NDC number is:

    16129-002-10 (10 mL)

    Storage

    Store at 20°C - 25°C (68°F - 77°F); excursions permitted to 15°C – 30°C (59°F – 86°F). Use the solution within 12 hours of the EOS reference time.

    Handling

    Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.

  • 17 PATIENT COUNSELING INFORMATION

    17.1 Pre-study Hydration

    Encourage patients to drink at least 500 mL of water prior to drug administration.

    17.2 Post-study Voiding

    To help protect themselves and others in their environment, patients should take the following precautions for 12 hours after injection: whenever possible, use a toilet and flush several times after each use; wash hands thoroughly after each voiding or fecal elimination. If blood, urine or feces soil clothing, wash the clothing separately.

  • SPL UNCLASSIFIED SECTION

    Manufactured by:
    Shertech Laboratories, LLC
    1185 Woods Chapel Rd.
    Duncan SC, 29334

    Distributed by:
    Shertech Laboratories, LLC
    1185 Woods Chapel Rd.
    Duncan SC, 29334

  • Principal Display Panel - 30 mL Lead Pig (Shield) Container Label

    Package Hot Cell Shield Label 30 mL Item # 100073
  • Principal Display Panel - Vial Label 30 mL

    Container Multidose Vial Label 30 mL Item # 100070
  • Principal Display Panel - 10 mL Lead Pig (Shield) Container Label

    10 mL Lead Pig (Shield) Container Label
  • Principal Display Panel - Vial Label 10 mL

    Vial Label 10 mL
  • INGREDIENTS AND APPEARANCE
    SODIUM FLUORIDE  F 18
    sodium fluoride f 18 injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 16129-002
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM FLUORIDE F-18 (UNII: 9L75099X6R) (FLUORIDE ION F-18 - UNII:4M4WE5N2GE) FLUORIDE ION F-18200 mCi  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 9 mg  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 16129-002-1010 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product03/23/2011
    2NDC: 16129-002-3030 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product03/23/2011
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20431503/23/2011
    Labeler - Shertech Laboratories, LLC (621117279)
    Establishment
    NameAddressID/FEIBusiness Operations
    Shertech Laboratories, LLC621117279positron emission tomography drug production(16129-002)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.